The State Scientific and Technological Progress Award Second-Class Award – Investigation of the Pathogenicity of Retinal Disease Genes and Promotion of Its Application in Disease Treatment and Prevention

The State Scientific and Technological Progress Award Second-Class Award – Investigation of the Pathogenicity of Retinal Disease Genes and Promotion of Its Application in Disease Treatment and Prevention

 

The research programme ‘Investigation of the Pathogenicity of Retinal Disease Genes and Promotion of Its Application in Disease Treatment and Prevention’ led by Prof. Zhenglin Yang of Sichuan Academy of Medical Sciences and Sichuan People’s Hospital, and Prof. Chi Pui Pang, S.H. Ho Professor of Visual Sciences and Professor of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong (CUHK), has been awarded the SSTPA Second- Class Award of State Science and Technology Progress Award.

The programme addresses two major categories of retinal diseases, age-related macular degeneration (AMD) and paediatric retinal diseases (PRD). The research group identified new disease genes and elucidated their roles in the disease pathogeneses, and established the genetic diagnosis and prevention platform for retinal diseases. The key accomplishments included: 1) Identification of the major genes for AMD. The group identified HTRA1 as the most important gene for AMD in the Chinese population, and unravelled its role in AMD mechanism, providing new insights into the therapy of AMD. This finding was listed as one of the top-10 scientific breakthroughs of 2006 by Science. 2) Establishment of AMD genetic risk prediction and disease treatment and prevention system for the Chinese population, reducing the occurrence of AMD and improving the therapeutic efficacy. 3) Establishment of a Big-data analysis platform and identification of new disease-causing genes for PRD, expanding the spectra of retinal disease genes and mutations. 4) Development of the PRD diagnostic gene chip, enabling precise diagnosis of PRD and providing therapeutic guidance. 5) Leading the PRD prenatal diagnosis and genetic consultation. Traditional screening of birth defect does not provide prenatal diagnosis of PRD. The group has developed a novel diagnostic gene chip for PRD and provided prenatal diagnosis service for over 70,000 individuals from 13 ophthalmic centres in 10 provinces and cities of mainland China.

Congratulations, Prof. Pang!

Calvin_Pang_1to1

For details of the award announcement, please visit:

http://www.most.cn/ztzl/gjkxjsjldh/jldh2016/jldh16jlgg/201701/t20170105_130203.htm